Payment overview · 2025
General Payments
$644.55
36 reported records · 15 companies
Healthcare provider profile · identity verified
Robert Henderson, DO
Allopathic & Osteopathic Physicians|Family Medicine · ROANOKE, VA · NPI 1356552376
Verified facts
What the public records show
CMS Open Payments records show Robert Henderson, DO received $644.55 in general payments during 2025 across 36 reported records.
AstraZeneca Pharmaceuticals LP accounted for 17.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 186 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $114.27 | 17.7% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $81.13 | 12.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.13 | 12.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.29 | 7.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.51 | 6.8% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.93 | 6.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.86 | 5.6% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.83 | 4.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $31.80 | 4.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.74 | 4.8% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.55 | 4.6% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.05 | 4.3% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.52 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.48 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.46 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $644.55 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $81.13 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $77.13 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $77.13 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $52.92 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.29 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.23 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $39.93 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.83 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $31.80 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.74 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.05 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $27.80 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $27.80 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $18.48 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 219 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 186 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 164 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
63 | 14 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
186 | 42 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 42 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
219 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 745 | 211 |
| Lisinopril | Lisinopril | 675 | 181 |
| Losartan Potassium | Losartan Potassium | 659 | 165 |
| Simvastatin | Simvastatin | 640 | 173 |
| Levothyroxine Sodium | Levothyroxine Sodium | 583 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 501 | 142 |
| Omeprazole | Omeprazole | 431 | 118 |
| Metformin Hcl | Metformin Hcl | 396 | 111 |
| Metoprolol Tartrate | Metoprolol Tartrate | 395 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 386 | 110 |
| Gabapentin | Gabapentin | 324 | 73 |
| Montelukast Sodium | Montelukast Sodium | 311 | 91 |
| Duloxetine Hcl | Duloxetine Hcl | 310 | 81 |
| Furosemide | Furosemide | 300 | 86 |
| Escitalopram Oxalate | Escitalopram Oxalate | 262 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 247 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 235 | 72 |
| Trazodone Hcl | Trazodone Hcl | 223 | 58 |
| Eliquis | Apixaban | 219 | 43 |
| Potassium Chloride | Potassium Chloride | 206 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 195 | 48 |
| Meloxicam | Meloxicam | 188 | 59 |
| Farxiga | Dapagliflozin Propanediol | 186 | 42 |
| Bupropion Xl | Bupropion Hcl | 179 | 38 |
| Fenofibrate | Fenofibrate | 178 | 45 |
| Sertraline Hcl | Sertraline Hcl | 177 | 42 |
| Pregabalin | Pregabalin | 176 | 34 |
| Ezetimibe | Ezetimibe | 167 | 54 |
| Jardiance | Empagliflozin | 164 | 42 |
| Buspirone Hcl | Buspirone Hcl | 161 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 40 |
| Allopurinol | Allopurinol | 140 | 34 |
| Bumetanide | Bumetanide | 133 | 30 |
| Famotidine | Famotidine | 132 | 32 |
| Januvia | Sitagliptin Phosphate | 125 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 122 | 18 |
| Ozempic | Semaglutide | 120 | 25 |
| Atenolol | Atenolol | 108 | 29 |
| Diclofenac Sodium | Diclofenac Sodium | 108 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 107 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 103 | 31 |
| Prednisone | Prednisone | 103 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 102 | 21 |
| Alendronate Sodium | Alendronate Sodium | 101 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 99 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 36 |
| Glipizide | Glipizide | 98 | 28 |
| Warfarin Sodium | Warfarin Sodium | 98 | 16 |
| Xarelto | Rivaroxaban | 89 | 24 |
| Naproxen | Naproxen | 86 | 25 |
| Carvedilol | Carvedilol | 85 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 26 |
| Mirtazapine | Mirtazapine | 75 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 74 | 14 |
| Donepezil Hcl | Donepezil Hcl | 73 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 18 |
| Synthroid | Levothyroxine Sodium | 63 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 61 | 47 |
| Spironolactone | Spironolactone | 61 | 17 |
| Glipizide Er | Glipizide | 60 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 60 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 11 |
| Enalapril Maleate | Enalapril Maleate | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Clonidine Hcl | Clonidine Hcl | 52 | 15 |
| Meclizine Hcl | Meclizine Hcl | 52 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 30 |
| Ondansetron Odt | Ondansetron | 48 | 17 |
| Rybelsus | Semaglutide | 48 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 15 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 12 |
| Celecoxib | Celecoxib | 43 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 43 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 15 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 42 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 12 |
| Lovastatin | Lovastatin | 41 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 38 | 11 |
| Glimepiride | Glimepiride | 37 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | suppressed |
| Alprazolam | Alprazolam | 36 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 36 | 11 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Etodolac | Etodolac | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 26 |
| Clotrimazole | Clotrimazole | 33 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 14 |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 32 | suppressed |
| Finasteride | Finasteride | 32 | 11 |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 13 |
| Valsartan | Valsartan | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Mupirocin | Mupirocin | 28 | 11 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 25 |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 25 | 20 |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | suppressed |
| Rexulti | Brexpiprazole | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Sulindac | Sulindac | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 13 |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Topiramate | Topiramate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 14 |
| Primidone | Primidone | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 16 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $644.55 · 36 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAMZYOS, CREON, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VRAYLAR, Veozah, XIFAXAN, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error